Hemab Therapeutics (COAG) Director Walbert Keli Receives Award

What Happened

• Walbert Keli, a director of Hemab Therapeutics Holdings, Inc. (COAG), received a derivative award covering 36,000 shares on September 24, 2026. The filing reports a transaction price of $0.00, indicating no cash was paid at grant. This was a grant/award (Form 4 transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: September 24, 2026; Form 4 filed September 25, 2026 (timely).
• Award size: 36,000 shares (derivative). Reported price: $0.00.
• Vesting: shares underlying the award vest in equal monthly installments over three years (from 9/24/2026 through 9/24/2029), subject to continuous service (per footnote).
• Shares owned after transaction: not specified in the filing.
• Filing timeliness: filed the next day — consistent with Form 4 reporting requirements.

Context

• This is a derivative grant (options/RSUs or similar) that creates a right to receive or acquire shares subject to vesting; it does not represent immediate sale or purchase of stock. Such awards are commonly part of compensation or director incentives and are not by themselves a direct market signal of buying or selling.